Megan Lynch/LinkedIn
Jun 16, 2026, 16:17
Megan Lynch: Thrilled to Join AstraZeneca
Megan Lynch, Global Product Leader, Cell Therapy Enterprise at AstraZeneca, shared a post on LinkedIn:
“I’m thrilled to share that I’m joining AstraZeneca as a Global Product Leader, Cell Therapy Enterprise.
Cell therapy is transforming how we treat patients across hem/onc, autoimmune, and rare disease.
Getting innovative medicines to patients and providers has always been my north star and I can’t wait to dig in.
Thank you to Margie Li, Margaret DiGuardo, Carsten Linnemann, Craig Maxwell, and Eva Piqué for your partnership throughout this process — I’m looking forward to what we’ll build together.
Here’s to what’s next.”
Stay updated with Hemostasis Today.
-
Jun 16, 2026, 16:00Denise M: Two Partners, One Mission – Securing the Future of Blood
-
Jun 16, 2026, 15:4910 Posts Not To Miss From EHA 2026
-
Jun 16, 2026, 15:48Yan Leyfman: Can a Blood Test Reveal which Cells in Your Body are Aging Fastest?
-
Jun 16, 2026, 15:24Hiteshi K.C. Chauhan: Oral Anticoagulant Reversal in Major Bleeding and Urgent Surgery
-
Jun 16, 2026, 14:50Abdulrahman Nasiri: Honored to Share our Research Contributions at the EHA 2026
-
Jun 16, 2026, 14:49An Overview of Bernard–Soulier Syndrome – ICHCC
-
Jun 16, 2026, 14:47David Walcott: Blood Supply as Essential Healthcare Infrastructure
-
Jun 16, 2026, 14:36Catalin Bobirca: EHA 2026 Showcases the Future of Hemoglobinopathies Care
-
Jun 16, 2026, 14:30Jeffrey Kallberg: Education and Advocacy at the Texas Bleeding Disorders Conference